Medicaid work requirements challenged in court

The Trump administration’s efforts to change the Medicaid program by allowing states to implement work requirements could be under threat as they are challenged in court and threatened by a new report that shows the steep cost of putting the changes into place.

Since the Trump administration announced states could apply to add Medicaid work requirements, nine states have received approvals for such programs. Some states, including Kentucky, have seen legal challenges to their programs, but more are considering applying to add similar programs to Medicaid. Kentucky's program has since been reinstated.

Currently, a panel of judges in the U.S. Court of Appeals for the District of Columbia is considering whether HHS was allowed to actually permit the program changes, Politico reported.

And the work requirements could come under further scrutiny after a Government Accountability Office report found the implementation costs are in the hundreds of millions, The Wall Street Journal reported. States did not have to provide cost estimates for implementing the work requirements when applying for approval. This is “inconsistent with federal control standards,” according to the WSJ.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.